IVA Stock Analysis: Buy, Sell, or Hold?
IVA - Inventiva S.A. American Depository Shares
$5.34
-0.33 (-5.82%)
▼
5d:
-2.55%
30d:
-12.89%
90d:
+16.09%
HOLD
MODERATE Confidence
Analysis Updated: Apr 7, 2026 12:00 AM ET
Earnings: May 25, 2026
Get Alerted When IVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IVA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IVA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IVA is currently trading at $5.34, which is considered oversold relative to its 30-day fair value range of $5.70 to $6.36.
Technical Outlook: Technically, IVA is in a strong uptrend. The price is currently testing key support at $5.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: IVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.13 (+183.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IVA is in a strong uptrend. The price is currently testing key support at $5.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: IVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.13 (+183.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.70 -
$6.36
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.8%)
- BULLISH: Trading 183.3% below Wall St target ($15.13)
Fair Price Analysis
30-Day Fair Range
$5.70 -
$6.36
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.20
Resistance Level
$6.25
Current Trend
Strong Uptrend
Technical data as of
Apr 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.20
Wall Street Target
$15.13
(+183.3%)
Revenue Growth (YoY)
105.2%
Share & Embed Analysis
Last updated: April 08, 2026 1:23 AM ET
Data refreshes hourly during market hours. Next update: 2:23 AM
Data refreshes hourly during market hours. Next update: 2:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 54 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 57 HOLD |
